The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

ESMO WCGIC 2022 | Challenges to be overcome in the use of ctDNA for colon cancer treatment

Name: Challenges to be overcome in the use of ctDNA for colon cancer treatment
Uploaded: 2022-06-29T00:00:00Z
Duration: 2 min 5 s
Description: Julien Taieb, MD, PhD, European Hospital Georges Pompidou, Paris, France, discusses the need for larger studies to confirm the use of circulating tumor DNA (ctDNA) as an indicator of minimal residual disease (MRD) in patients with colon cancer. This interview took place at the European Society for Medical Oncology World Congress on Gastrointestinal Cancer (ESMO WCGIC) 2022 in Barcelona, Spain.

Julien Taieb • 29 Jun 2022

ESMO WCGIC 2022

Colon Cancer Gastrointestinal Cancer

Julien Taieb, MD, PhD, European Hospital Georges Pompidou, Paris, France, discusses the need for larger studies to confirm the use of circulating tumor DNA (ctDNA) as an indicator of minimal residual disease (MRD) in patients with colon cancer. This interview took place at the European Society for Medical Oncology World Congress on Gastrointestinal Cancer (ESMO WCGIC) 2022 in Barcelona, Spain.